Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 503 participants.

Also called NCT01582854

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 503 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01582854
  • WHO UTN U1111-1132-3434
Other papers using this trial's data
  • ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment Stroke, 2017-05 DOI, PubMed 28432265, PMC5404405 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belarus, Kazakhstan, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01582854. Randomized; double masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2016-02-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Acronym
ARTEMIDA
Condition
Post-Stroke Cognitive Impairment (PSCI)
Intervention (Drug)
Actovegin
Intervention (Drug)
Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01582854
Content hash
73732d731eb3cf22ae29ef4c1377d1b669f7fbea43699ac0b7aa1d069f2092d8